Mexico Pharmaceuticals and Healthcare Report Q2
2013

Mexico Pharmaceuticals and Healthcare Report Q2 2013

BMI View: Mexico's relatively low-cost business environment, growing domestic pharmaceutical market and the improving regulatory regime have made it an attractive market to multinationals.

The improved performance by market regulator COFEPRIS has allowed Mexico to acquire a reputation for early, speedy approvals of medicines that meet urgent local epidemiological needs and allow direct access to other robust growing pharmaceutical markets in Latin America..

Headline Expenditure Projections

• Pharmaceuticals: MXN176.00bn (US$13.36bn) in 2012 to MXN191.58bn (US$14.97bn) in 2013; +8.9% in local currency terms and +12% in US dollar terms.

Forecasts increasefrom Q113 due to improving industry environment.

• Healthcare: MXN965.46bn (US$73.31bn) in 2012 to MXN1,046.9bn (US$81.79bn) in 2013; +8.4% in local currency terms and +11.6% in US dollar terms.

Forecasts increase from Q113 due to improving industry environment.

• BMI Industry View
  • SWOT
  • Political
  • Economic
  • Business Environment
  • Industry Forecast
  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales Indicators 2009-2017
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Indicators 2009-2017
    • Table: Healthcare Governmental Indicators 2009-2017
    • Table: Healthcare Private Indicators 2009-2017
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Sales Indicators 2009-2017
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators 2009-2017
  • Generic Drug Market Forecast
    • Table: Generic Drug Sales Indicators, 2009-2017
  • OTC Drug Market Forecast
    • Table: OTC Medicine Sales Indicators 2009-2017
  • Pharmaceutical Trade Forecast
    • Table: Trade Indicators 2009-2017
  • Other Healthcare Data Forecasts
  • Key Risks To BMI's Forecast Scenario
  • Economic Analysis
    • Table: MEXICO - GDP CONTRIBUTION TO GROWTH
  • Industry Risk Reward Ratings
    • Table: Americas Pharmaceutical And Healthcare Risk/Reward Ratings, Q213
  • Rewards
  • Risks
  • Market Overview
  • Industry Trends And Developments
  • Epidemiology
  • Healthcare Sector Funding
  • Medical Tourism
  • Research & Development
  • Clinical Trials
    • Table: Clinical Trial Regulation In Mexico
  • Regulatory Development
  • Regulatory Development
  • Biologics And Biosimilar Guidelines
  • Intellectual Property Issues
    • Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights
  • Counterfeit Drugs
  • Pricing & Reimbursement
  • Reimbursement
  • Pricing Issues
  • Other Regulatory Developments
  • Competitive Landscape
  • Pharmaceutical Sector
  • Domestic Industry
    • Table: AstraZeneca Sales, 2005-10
  • Pharmaceutical Distribution
  • Pharmaceuticals Retail Sector
    • Table: IMSS Financial Indicators, 2000-11 (MXNmn)
    • Table: SPSS Budget, 2004-11 (MXNmn)
  • Other Developments
  • Company Profile
  • Genomma Labs
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Sanofi
  • Eli Lilly
  • Bristol-Myers Squibb
  • Novartis
  • Bayer
  • Boehringer Ingelheim
  • Merck KGaA
  • Roche Syntex
  • Demographic Forecast
  • Mexico Demographic Data
    • Table: Mexico's Population By Age Group, 1990-2020 ('000)
    • Table: Mexico's Population By Age Group, 1990-2020 (% of total)
    • Table: Mexico's Key Population Ratios, 1990-2020
    • Table: Mexico's Rural And Urban Population, 1990-2020
  • Glossary
  • Methodology
  • Methodology
  • Risk/Reward Ratings Methodology
  • Ratings Overview
    • Table: Pharmaceutical Business Environment Indicators
  • Weighting
    • Table: Weighting Of Components
  • Sources